Search

Displaying results 1251 - 1260 of 10000 in total
  1. Drug

    Methylene blue

    go.drugbank.com/drugs/DB09241
    ApprovedInvestigational

    Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. … Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia.

    Mixtures: UR N-C Urinary Antiseptic, Urin D/SCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, MATE 1 Inhibitors
  2. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. … (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety[A32469].

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsSynonyms: (1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol, (−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
  3. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.

    Synonyms: -ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-, -GLUTAMYL-L-TYROSYL-L-PROLYL-(2S)-2-CYCLOHEXYLGLYCYL-N6-(3Products: Zılbrysq 16,6 mg/0,416 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet), Zılbrysq 23 mg/0,574 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet)
  5. Drug

    Magnesium sulfate

    go.drugbank.com/drugs/DB00653
    ApprovedInvestigationalVet approved

    A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. … It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions.

    Synonyms: magnesium(II) sulfate, Magnesium sulfate (1:1)Mixtures: Vamin N, Tis-U-Sol
  6. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338] … Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase

  7. Drug

    Benserazide

    go.drugbank.com/drugs/DB12783
    ApprovedInvestigational

    A decarboxylase inhibitor like benserazide is consequently an effective compound to combine with levadopa as it is incapable of crossing the blood-brain barrier itself but acts to prevent the formation … This can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence [F2, L2553].

    Mixtures: Prolopa Cap 100-25, Prolopa Cap 200-50Categories: Aromatic L-amino Acid Decarboxylase Inhibitors
  8. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.

    Products: CABLIVI®, Cablivi 10 mg/1 mL Enjeksiyonluk Çözelti Hazırlamak İçin Toz ve Çözücü, 1 ADET
  9. Target

    Rho-associated protein kinase 1

    go.drugbank.com/bio_entities/BE0001016
    TargetHumans

    Protein kinase which is a key regulator of the actin cytoskeleton and cell polarity (PubMed:10436159, PubMed:10652353, PubMed:11018042, PubMed:11283607, PubMed:17158456, PubMed:18573880, PubMed:19131646, PubMed:8617235, PubMed:9722579). ...

    Synonyms: ROCK-I, Rho-associated, coiled-coil-containing protein kinase I
  10. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).

    Products: ARIXTRA ® 10MG /0.8 ML, ARIXTRA ® 7.5 MG /0.6 ML